Almost one third of the new therapeutics approved by the FDA between 2001 and 2010 were affected by a postmarket safety event, according to a recent study conducted at Brigham and Women’s Hospital in Boston, Massachusetts.
- Downing NS, Shah ND, Aminawung JA, et al. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA. 2017;317(18):1854-1863. doi:10.1001/jama.2017.5150